Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.